NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Nammi Therapeutics

Nammi Therapeutics

Private
Los Angeles, CaliforniaHealthcare & Life Scienceshttps://www.nammirx.com/

Last Round

Series B

Nov 8, 2024

Total Funding Raised

$82.2M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Nammi Therapeutics is a biotechnology company that develops innovative immunotherapy solutions, including masked immunocytokines and nanoparticle-based prodrugs, for the treatment of cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

immuno-oncologymasked immunocytokineMICtargeted cancer therapydrug delivery platformnanoparticle drug deliverysolid lipid nanoparticleSLNPtumor microenvironmentprecision medicineprodrugbiotech startupclinical-stage biotechcancer drug development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Nammi Therapeutics Comparables

Compare Nammi Therapeutics with similar companies based on industry and business-model similarity.

Nammi Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Werewolf Therapeutics
81%
Asher Biotherapeutics
80%
CytomX Therapeutics
79%

Nammi Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BNov 8, 2024
Series BAug 6, 2024
GrantDec 15, 2022
SeedJan 1, 2019

Key People

Founding team and executive leadership

Joseph Rice

Chief Financial Officer and EVP of Operations, Executive Vice President of Operations

Executive Team

Nammi Therapeutics Investors

Notable investors and investment history

Nammi Therapeutics investors
InvestorRounds
California Institute for Regenerative MedicineGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 16, 2026

    Monthly visitors grew 40% MoM to 1.8K.

  • Dec 15, 2022

    $4M grant from California Institute for Regenerative Medicine.

Nammi Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Nammi Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Nammi Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersLos Angeles, California
Employee Range9
Year Founded2018
Last FundingNov 8, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.